Effect of Intranasal Anti-IgE Antibodies on IgE Production
Effect of Intranasal Anti-IgE Antibodies on IgE Production
In this study, participants will receive either intranasal anti-IgE-antibodies (n=5) or
 intranasal allergen (n=5) or intranasal placebo (n=5). Blood samples will be obtained before
 nasal administration of study drugs and 3, 5 and 8 weeks thereafter. In the serum samples,
 specific and total IgE levels will be assessed.
The intranasal challenge study will be performed over 8 weeks outside of the birch pollen
 season (November to January) as a randomized, double blind and placebo-controlled study.
 During a screening visit, 15 individuals will be recruited according to eligibility criteria.
 They will be randomized into 3 groups (i.n. administration of anti-IgE antibodies, Bet v 1 or
 placebo). Intranasal administration will take place on three consecutive days and serum
 samples will be taken 3, 5, and 8 weeks (+/- 4 days) after the treatment for analysis of
 total and specific IgE levels
Inclusion Criteria:

 birch pollen allergy

 Exclusion Criteria:

 history of anaphylaxis autoimmune diseases treatment with corticosteroids, antihistamines,
 immunosuppressant drugs, beta-blockers significant medical conditions pregnancy or
 lactation